[CLINICAL EVALUATION OF THE NEW ANTISEPTIC MESHES].

Georgian Med News

I. Javakhishvili Tbilisi State Universiti, Medical Department, Faculty of Medicine.

Published: December 2016

Improving the results of hernia treatment and prevention of complications became a goal of our research which included two parts - experimental and clinical. Histomorphological and bacteriological researches showed that the best result out of the 3 control groups was received in case of covering implant "Coladerm"+ with chlorhexidine. Based on the experiment results working process continued in clinics in order to test and introduce new "coladerm"+ chlorhexidine covered poliprophilene meshes into practice. For clinical illustration there were 60 patients introduced to the research who had hernioplasty procedures by different nets: I group - standard meshes+"coladerm"+chlorhexidine, 35 patients; II group - standard meshes +"coladerm", 15 patients; III group - standard meshes, 10 patients. Assessment of the wound and echo-control was done post-surgery on the 8th, 30th and 90th days. This clinical research based on the experimental results once again showed the best anti-microbe features of new antiseptic polymeric biocomposite meshes (standard meshes+"coladerm"+chlorhexidine); timely termination of regeneration and reparation processes without any post-surgery suppurative complications. We hope that new antiseptic polymeric biocomposite meshes presented by us will be successfully used in surgical practice of hernia treatment based on and supported by expermental-clinical research.

Download full-text PDF

Source

Publication Analysis

Top Keywords

group standard
12
hernia treatment
8
"coladerm"+ chlorhexidine
8
standard meshes+"coladerm"+chlorhexidine
8
standard meshes
8
antiseptic polymeric
8
polymeric biocomposite
8
biocomposite meshes
8
meshes
5
[clinical evaluation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!